CN103316015B - Medicine for treating epistaxis through oral administration and external use and method thereof - Google Patents
Medicine for treating epistaxis through oral administration and external use and method thereof Download PDFInfo
- Publication number
- CN103316015B CN103316015B CN201310259134.0A CN201310259134A CN103316015B CN 103316015 B CN103316015 B CN 103316015B CN 201310259134 A CN201310259134 A CN 201310259134A CN 103316015 B CN103316015 B CN 103316015B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- oral administration
- blood
- epistaxis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 208000001780 epistaxis Diseases 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 13
- 229960002588 cefradine Drugs 0.000 claims abstract description 12
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims abstract description 12
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 claims abstract description 12
- 229960001625 furazolidone Drugs 0.000 claims abstract description 12
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims abstract description 10
- 229960005091 chloramphenicol Drugs 0.000 claims abstract description 7
- 238000002347 injection Methods 0.000 claims abstract description 7
- 239000007924 injection Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940097572 chloromycetin Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 10
- 208000032843 Hemorrhage Diseases 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 230000000740 bleeding effect Effects 0.000 abstract description 2
- 241000218691 Cupressaceae Species 0.000 abstract 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 2
- 240000004064 Poterium sanguisorba Species 0.000 abstract 2
- 235000008291 Poterium sanguisorba Nutrition 0.000 abstract 2
- 241000405414 Rehmannia Species 0.000 abstract 2
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 2
- 235000011477 liquorice Nutrition 0.000 abstract 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 210000003928 nasal cavity Anatomy 0.000 description 7
- 244000045947 parasite Species 0.000 description 6
- 108090000190 Thrombin Proteins 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003135 vibrissae Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 241000237903 Hirudo Species 0.000 description 2
- 206010065954 Stubbornness Diseases 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicine for treating epistaxis through oral administration and external use and a method thereof. The following components are combined for use as the medicine in parts by weight: 0.5 part of chloramphenicol tablets, 0.5 part of cefradine injection powder, 0.5 part of furazolidone tablets, 30 parts of radix rehmanniae, 30 parts of prepared rhizome of rehmannia, 25 parts of garden burnet root, 30 parts of golden cypress, 30 parts of fructus forsythiae, 25 parts of caulis spatholobi and 25 parts of liquorice, wherein western medicines, namely the chloramphenicol tablets, the cefradine and the furazolidone tablets, are bactericidal medicines for external use, and wherein traditional Chinese medicines, namely radix rehmanniae, prepared rhizome of rehmannia, garden burnet root, golden cypress, 30 parts of fructus forsythiae, caulis spatholobi and liquorice are decocted with water and used as medicines for oral administration. The medicine provided by the invention is obvious in medicine treatment effect, quick to stop bleeding and worthy of popularization and utilization.
Description
Technical field
Fa of the present invention and a kind of medicine that can have good therapeutic effect to epistaxis, belong to medical domain.
Background technology
At the body part of people, there is a lot of place at the position can not bled voluntarily because of the attack of applied external force, as: cerebral hemorrhage, gastrorrhagia, dental hemorrhage, epistaxis etc., brain, stomach, tooth, nose, the blood vessel at these positions is abundanter, particularly blood capillary is comparatively flourishing, and the tube wall of blood vessel is more fragile, wherein common with epistaxis.The boundary having the population ages of epistaxis symptom also not determine, has old man also to have child, but in the majority with older person.The causes for pathological more complicated of epistaxis, has the reason of blood, also has the reason of liver, the reason also having outside antibacterial to invade, also has parasitic reason etc., for the epistaxis of someone, just can not can draw nosogenetic conclusion for the moment.The reason of our first analyzing blood: vertebrate blood has automatic hemorrhage coagulation function, when angiorrhexis, thrombin in blood plasma can be gathered in wound place and form blood clotting plate obstruction blood continuation outflow, these thrombins comprise Fibrinogen, platelet, many Cao body fibrin etc., if in blood plasma these thrombins shortage or suffer to destroy the obstacle that all can cause hemostasis.The liver deficiency of YIN of people or liver-fire rise or the random function pathological changes that also indirectly can cause hemostasis of liver function sequence.The invasion of outside antibacterial also can destroy the hemostatic function of blood, and some antibacterials can hinder the assembly of thrombin and can disassemble sludged blood and make wound place unblocked.Intranarial parasite also plays the effect hindering hemostasis to epistaxis, the secretions of Hirudo can destroy the assembly of blood clotting factor, and the secretions of the parasite generation of the similar Hirudo had also can destroy the assembly of blood clotting factor, and blood vessel wound can not be stopped blooding.
The general incident of epistaxis phenomenon is unexpected, bleeds and incessantly likely causes the danger of life, and having the conveying patient examination in hospital of unexpected epistaxis to treat may have little time, and must take measures as early as possible to save oneself.At present, people occur that the measure that epistaxis is taked uses Cotton Gossypii directly to clog nostril, this method also can receive certain effect, but somebody clog nostril still have blood constantly from plug mouth infiltrate, blood can also flow to oral cavity, the pulmonary of people from the top in nostril; Some patients clog nostril hemostasis, but one takes away tamper, at once flow out blood again.For the medicine for the treatment of epistaxis, really varied, because the reason of epistaxis has many reasons.
Summary of the invention
In order to the patient of epistaxis can obtain hemostatic treatment fast, the medicine of a kind of oral administration and externally treatment of my invention epistaxis, this composition of medicine can make epistaxis stop blooding as early as possible, and medicine obtains capacity, method that is for oral administration, external is all comparatively simple.
The present invention deals with problems taked technical scheme by weight ratio composition of medicine below: Chloramphenicol Tablets 0.5 part, cefradine injection powder 0.5 part, Furazolidone tablet 0.5 part, 30 parts, Radix Rehmanniae Preparata, 30 parts, the Radix Rehmanniae, Radix Sanguisorbae 25 parts, Cortex Phellodendri 30 parts, Fructus Forsythiae 30 parts, Caulis Spatholobi 25 parts, 25 parts, Radix Glycyrrhizae.Western medicine is had also to have Chinese medicine in medicine listed above, its chloromycetin of western medicine sheet 0.5 part, cefradine injection powder 0.5 part, Furazolidone tablet 0.5 part are as external, and 30 parts, Chinese medicine Radix Rehmanniae Preparata, 30 parts, the Radix Rehmanniae, Radix Sanguisorbae 25 parts, Cortex Phellodendri 30 parts, Fructus Forsythiae 30 parts, Caulis Spatholobi 25 parts, 25 parts, Radix Glycyrrhizae make medication for for oral administration.
The antibiotics Chloramphenicol and cefradine with sterilizing function is employed in the medicine of oral administration and externally treatment epistaxis of the present invention, but these two kinds of antibiotic do not use simultaneously, just respectively the interval uses, and is the mutual complementarity of safety in order to use and sterilizing like this.Also use another kind in medicine of the present invention and kill colibacillary medicine Furazolidone tablet, the furazolidone aqueous solution of high concentration not only can kill a lot of pathogenic bacteria, and can eliminate and parasitize the small parasite of nasal cavity.In fact, above-listed three kinds of Western medicine all can take orally, but antibiotic for oral administration or bactericide have certain quantitative limitation, like this, these medicines can only arrive the hemorrhage wound of nasal cavity from blood with extremely low concentration, the pathogenic bacteria of the stubbornness at wound place is not constituted a threat to, some pathogenic bacterias be stick to nasal cavity vibrissa on or mucous layer, the medicine in blood can not arrive at all eliminates them.The oral administration of chloromycetin, cefradine, furan file ketone these three kinds of medicines makes them enter human body on a small quantity and also can not cause safety problem being had in the process of nasal cavity external.
Except use Western medicine sterilizes, the Chinese medicine that the character of blood is nursed one's health is also used in the medicine of oral administration and externally treatment epistaxis of the present invention, mainly based on removing heat from blood, enrich blood, liver heat removing is invigorated blood circulation, invigorate blood circulation and fall the Chinese medicine of blood, can increase, activate thrombin, the assembly ability of thrombin in blood can be strengthened.Such as: effect that the Radix Rehmanniae, Radix Rehmanniae Preparata use removing heat from blood to enrich blood together; Radix Sanguisorbae has effect that liver heat removing spleen is hot and suffocating, stop blooding; Cortex Phellodendri has pathogenic fire reducing YIN nourishing, bone in damp and hot effect; Effect that Fructus Forsythiae has the virus that can disappear, gas gathers blood clotting; Egg blood Teng has blood circulation promoting and blood stasis dispelling, can disappear damp and hot effect; Effect of Radix Glycyrrhizae energy heat-clearing and toxic substances removing, coordinating the actions of various ingredients in a prescription.
The beneficial effect of the medicine of oral administration and externally of the present invention treatment epistaxis is: can attack from being stained with rete, vibrissa of nasal cavity the antibiotic medicine that the pathogenic bacteria of stubbornness carries out high concentration, and can nurse one's health with the blood properties of the method for Chinese medicine for oral administration to people, invigorate blood circulation, removing heat from blood, to enrich blood, and can liver heat removing reason spleen, strengthen the cohesion hemostatic capability of thrombin in blood.
Detailed description of the invention
Further illustrate with two embodiments below.
Embodiment 1, the medicine in the medicine of oral administration and externally treatment epistaxis is by mass ratio combination below: Chloramphenicol Tablets 0.5 gram (5), Furazolidone tablet 0.5 (5), 30 grams, the Radix Rehmanniae, 30 grams, Radix Rehmanniae Preparata, Radix Sanguisorbae 25 grams, Cortex Phellodendri 30 grams, Fructus Forsythiae 30 grams, Caulis Spatholobi 25 grams, 25 grams, Radix Glycyrrhizae.Using method: one, by Chloramphenicol Tablets 5 and the pure powdered mix homogeneously of Furazolidone tablet 5 pressure, spreads into nostril by the powder fractions of gained; If bleed in nostril, amount of powder is sprinkled on one little cotton wool and fill in nostril, and raise one's head and allow powder be dissolved in blood several times, changed medicated powder and Cotton Gossypii every 4 hours once.Two, by 30 grams, the Radix Rehmanniae, 30 grams, Radix Rehmanniae Preparata, Radix Sanguisorbae 25 grams, Cortex Phellodendri 30 grams, Fructus Forsythiae 30 grams, Caulis Spatholobi 25 grams, 25 grams, Radix Glycyrrhizae with clear water infiltrate after and two liters, water decoct 30 minutes, the medicinal liquid of about 1 liter decocting rear gained is divided and takes for three times, within every four hours, take once.Using method is above carried out every day, and using continuously four days is a course for the treatment of.General Epistaxis Patients use drug regimen of the present invention and method one day afterwards initiatively hemorrhage symptom can be inhibited, if the Epistaxis Patients that causes of infective or parasite just obtains haemostatic effect at use drug regimen of the present invention in ten minutes.
If use the epistaxis patient of embodiment 1 still to can not receive good therapeutic effect, can use embodiment two, the medicine of oral administration and externally treatment epistaxis and the medicine of method are by mass ratio combination below: cefradine injection powder 0.5 gram, Furazolidone tablet 0.5 gram (5), 30 grams, the Radix Rehmanniae, 30 grams, Radix Rehmanniae Preparata, Radix Sanguisorbae 25 grams, Cortex Phellodendri 30 grams, Fructus Forsythiae 30 grams, Caulis Spatholobi 25 grams, 25 grams, Radix Glycyrrhizae.Using method: one, is crushed to powder and cefradine injection powder 0.5 gram of mix homogeneously by Furazolidone tablet 5, this mixed powder end taken a morsel is faced upward head and spread in nostril; If bleed in nostril, the mixed powder end taken a morsel is filled in nostril after sprinkling a cotton wool and is faced upward and allows for several leading time medicated powder dissolving enter blood, and the medicine blood mixed liquor of high concentration can arrive each position in nostril.Two, get 30 grams, the Radix Rehmanniae, Radix Rehmanniae Preparata 30, Radix Sanguisorbae 25 grams, Cortex Phellodendri 30, Fructus Forsythiae 30 grams, Caulis Spatholobi 25 grams, 25 grams, Radix Glycyrrhizae with after water infiltration and two liters, water decoct the medicinal liquid obtaining about a liter after 30 minutes, the medicinal liquid of this liter is divided and takes orally for three times, took once every four hours.Using method is above carried out every day, and carrying out continuously four days is a course for the treatment of.Patients with uncontrolled epistaxis is moved hemorrhage symptom at use drug regimen of the present invention and method one day rear and can be controlled, if the epistaxis that infectivity and parasite cause just obtains haemostatic effect in one hour in medication.Employ the antibiotic cefradine more having extensive sterilizing power in embodiment two, the cefradine of the high concentration of external more can be eliminated in nasal cavity to illegally occupy and be stained with the pathogenic bacteria on rete or vibrissa in the blood flow at wound place.The furan file ketone being dissolved in the high concentration in the blood of outflow can kill the parasite illegally occupying and to be stained with at nasal cavity on rete or vibrissa rapidly.
Implementation result: the medicine of oral administration and externally treatment epistaxis of the present invention has used 31 routine Epistaxis Patients in since this clinic business 3 years, wherein 19 routine patients stop in ten minutes hemorrhage at use embodiment 1 medicine, and medication was fully recovered after the course for the treatment of; Five routine patients use embodiment 1 medicine one day afterwards initiatively bleeding be inhibited, medication was fully recovered after the course for the treatment of; Three routine patients are DeGrain after the course for the treatment of of medicine using embodiment 1, stopped hemorrhage after using the medicine of embodiment 2 instead in ten minutes, fully recovers after using a course for the treatment of of medicine of embodiment 2; One routine patient after using medicine one sequence course for the treatment of of embodiment 2 initiatively the symptom of epistaxis be inhibited, but to recur again after ten days; Three routine patients turn hospitalize after using the medicine of embodiment 1 and using the medicine of embodiment 2 to lose effect.
Claims (2)
1. the medicine of oral administration and externally treatment epistaxis, is characterized in that combining by drug quality ratio below: Chloramphenicol Tablets 0.5 part, cefradine injection powder 0.5 part, Furazolidone tablet 0.5 part, 30 parts, the Radix Rehmanniae, 30 parts, Radix Rehmanniae Preparata, Radix Sanguisorbae 25 parts, Cortex Phellodendri 30 parts, Fructus Forsythiae 30 parts, Caulis Spatholobi 25 parts, 25 parts, Radix Glycyrrhizae.
2. the medicine of oral administration and externally treatment epistaxis according to claim 1, is characterized in that: the chloromycetin of western medicine sheet in the present invention 0.5 part, cefradine injection powder 0.5 part, Furazolidone tablet 0.5 part are as medicine for external use; The water decoction of 30 parts, the Chinese medicine Radix Rehmanniae in the present invention, 30 parts, Radix Rehmanniae Preparata, Radix Sanguisorbae 25 parts, Cortex Phellodendri 30 parts, Fructus Forsythiae 30 parts, Caulis Spatholobi 25 parts, 25 parts, Radix Glycyrrhizae makes medication as oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310259134.0A CN103316015B (en) | 2013-06-26 | 2013-06-26 | Medicine for treating epistaxis through oral administration and external use and method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310259134.0A CN103316015B (en) | 2013-06-26 | 2013-06-26 | Medicine for treating epistaxis through oral administration and external use and method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103316015A CN103316015A (en) | 2013-09-25 |
| CN103316015B true CN103316015B (en) | 2015-05-27 |
Family
ID=49185249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310259134.0A Active CN103316015B (en) | 2013-06-26 | 2013-06-26 | Medicine for treating epistaxis through oral administration and external use and method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103316015B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623054A (en) * | 2013-11-13 | 2015-05-20 | 蒋世芬 | Medicine and method for treating persistent bleeding of nasal mucosa |
| CN105030958A (en) * | 2015-08-27 | 2015-11-11 | 赵文华 | Pharmaceutical composition and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101745041A (en) * | 2008-12-19 | 2010-06-23 | 宋慧婷 | Chinese medicine prescription for treating nosebleed |
| CN102218132B (en) * | 2011-06-09 | 2012-12-26 | 杨友成 | Medicinal composition for treating nasal bleeding |
-
2013
- 2013-06-26 CN CN201310259134.0A patent/CN103316015B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103316015A (en) | 2013-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614440B (en) | Multi-herb antibacterial liquid | |
| CN101843787B (en) | Chinese medicament for treating benign prostatic hyperplasiabrain | |
| CN101843699B (en) | Chinese medicament for treating benign prostatic hyperplasiabrain | |
| CN101843694A (en) | Chinese medicament for treating chronic hepatitis | |
| CN103316015B (en) | Medicine for treating epistaxis through oral administration and external use and method thereof | |
| CN101919927A (en) | Spray for promoting scald healing | |
| CN102824449B (en) | A kind of external-use tincture for the treatment of decubital ulcer, traumatic infection, diabetic dermopathy | |
| CN101822778B (en) | Traditional Chinese medical combination for preventing and curing HFMD and preparation method thereof | |
| CN103432551A (en) | Externally applied medicine for treating scapulohumeral periarthritis, radiohumeral bursitis and inexplicable ostalgia | |
| CN101843804A (en) | Chinese medicament for treating benign prostatic hyperplasiabrain | |
| CN115486488A (en) | Tea drink composition for common food and application thereof | |
| CN102389547A (en) | Traditional Chinese medicine for treating diabetic foot | |
| CN104623054A (en) | Medicine and method for treating persistent bleeding of nasal mucosa | |
| CN104117018A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN101843759B (en) | Oral Chinese medicament for treating fracture | |
| CN101843721B (en) | Chinese medicament for treating psoriasis | |
| CN101843738A (en) | Chinese medicament for treating diabetic feet | |
| CN102018839A (en) | Medicinal wine for dissolving thrombus and prolonging life | |
| CN105560893A (en) | Traditional Chinese medicine composition for treating periodontitis | |
| CN104587394A (en) | Traditional Chinese medicine composition for treating delayed union and nonunion | |
| CN101843799B (en) | Oral Chinese medicament for treating fracture | |
| CN101843859B (en) | Chinese medicament for treating psoriasis | |
| CN102018760A (en) | Traditional Chinese medicine for treating benign prostatic hyperplasia | |
| CN105477098A (en) | Traditional Chinese medicine composition for recovery from cerebral thrombosis | |
| CN104306734A (en) | Plaster preparation for external use for treating diabetic gangrene and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Fangcheng District of Fangchenggang city the Guangxi Zhuang Autonomous Region 538000 town Yuen Street No. 24 Applicant after: Li Xianqiang Address before: 536800 port 131, Fangchenggang Port Road, the Guangxi Zhuang Autonomous Region, China Applicant before: Li Xianqiang |
|
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 536000 the Guangxi Zhuang Autonomous Region, Hangzhou Road, low rent housing district, building 2-302, room 4, Applicant after: Li Xianqiang Address before: Fangcheng District of Fangchenggang city the Guangxi Zhuang Autonomous Region 538000 town Yuen Street No. 24 Applicant before: Li Xianqiang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 538000 FANGCHENGGANG, GUANGXI ZHUANG AUTONOMOUS REGION TO: 536000 BEIHAI, GUANGXI ZHUANG AUTONOMOUS REGION |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 536000 the Guangxi Zhuang Autonomous Region stars Fangcheng District of Fangchenggang City Road 5 lane 13 Patentee after: Li Xianqiang Address before: 536000 the Guangxi Zhuang Autonomous Region, Hangzhou Road, low rent housing district, building 2-302, room 4, Patentee before: Li Xianqiang |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181213 Address after: 233010 409 Wu Wan Road, Yuhui District, Bengbu, Anhui Patentee after: BENGBU JINSHI NEW MATERIAL Co.,Ltd. Address before: 230031 B-1014, 10 floor, business office building, Wo Ye garden, Shushan District, Hefei, Anhui. Patentee before: HEFEI WISDOM LOTUT INTELLECTUAL PROPERTY Co.,Ltd. Effective date of registration: 20181213 Address after: 230031 B-1014, 10 floor, business office building, Wo Ye garden, Shushan District, Hefei, Anhui. Patentee after: HEFEI WISDOM LOTUT INTELLECTUAL PROPERTY Co.,Ltd. Address before: 536000 Fangchenggang City, Guangxi Zhuang Autonomous Region, No. 13, Lane 5, Fangcheng Group Star Road Patentee before: Li Xianqiang |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190527 Address after: 437000 No. 16 Xingning Road, Biomedical Industrial Park, Xian'an Economic Development Zone, Xianning City, Hubei Province Patentee after: Zhenao Honeysuckle Pharmaceutical Co.,Ltd. Address before: 233010 409 Wu Wan Road, Yuhui District, Bengbu, Anhui Patentee before: BENGBU JINSHI NEW MATERIAL Co.,Ltd. |